One Molecule, Nearly 24 Million Spectra

• October 7, 2026

FDA approves combo for ESR1-mutated breast cancer

In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.

• by Kathryn Wighton

• September 21, 2026

• 2 min

Diagnostic accuracy of the Active Melioidosis Detect Plus rapid test for detection of Burkholderia pseudomallei in throat swabs

• by Arjun Chandna, Sena Sao, Joy Silisouk, Amphone Sengduangphachanh, Thyl Miliya, David A.B. Dance, Sue J. Lee, Koukeo Phommasone, Keang Suy, Tamalee Roberts, Clare L. Ling

• September 25, 2026

Kidney Testing Gets Under the Skin

A microneedle platform captured a kidney injury biomarker from interstitial fluid

• September 22, 2026

• 3 min